AKBA - Akebia Therapeutics, Inc.
6.30 0.00 (0.00%)
After hours: 4:34PM EST
| Previous Close | 6.18 |
| Open | 6.15 |
| Bid | 6.11 x 4000 |
| Ask | 7.19 x 1200 |
| Day's Range | 6.11 - 6.37 |
| 52 Week Range | 5.20 - 15.78 |
| Volume | 323,243 |
| Avg. Volume | 1,004,060 |
| Market Cap | 736.394M |
| Beta (3Y Monthly) | 3.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | Mar 11, 2019 - Mar 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.43 |
- Business Wire•15 days ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six newly-hired employees options to purchase an aggregate of 45,150 shares of Akebia’s common stock on December 31, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $5.53 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Business Wire•16 days ago
Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30 a.m. Pacific Time at the Westin St. Francis in San Francisco. A live webcast of the presentation will be available on the company’s website at www.akebia.com. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.
- Insider Monkey•last month
Hedge Funds Are Crazy About Akebia Therapeutics Inc (AKBA)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]
GuruFocus.com•last monthSeth Klarman Gains Stake in Akebia Therapeutics
Legendary investor Seth Klarman (Trades, Portfolio) disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals (KERX) closed as it converted into a stake in Akebia Therapeutics (AKBA) upon the merger of the two companies. Warning! GuruFocus has detected 2 Warning Signs with TBPH.
- Insider Monkey•last month
Abrams Capital Management’s Return, AUM and Holdings
An intriguing billionaire, David Abrams launched his own investment firm Abrams Capital Management back in 1999 in Boston, and he has run it very successfully so far. When we say intriguing, we refer to David Abrams’ low profile and interesting investment strategy. Let’s start from the beginning – David Abrams graduated from the University of Pennsylvania […]
- Benzinga•last month
Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says
Akebia Therapeutics Inc (NASDAQ: AKBA ) announced shareholder approval this week for its merger with Keryx Biopharmaceuticals (NASDAQ: KERX ). The Analyst Analyst Reni Benjamin of Raymond James maintains ...
- Motley Fool•last month
Why Akebia Therapeutics Is Soaring Today
Traders cheer after the company completes its merger agreement. Here's what investors need to know.
- Business Wire•last month
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the potential to set new standards of care for patients with kidney disease," said John P. Butler, President and Chief Executive Officer of Akebia. "With established renal development, manufacturing and commercial capabilities, strong cash position, a flexible balance sheet and experienced management team, our company is uniquely positioned to capitalize on the significant market opportunity by maximizing the growth of Auryxia® (ferric citrate) and build launch momentum for our Phase 3 product candidate, vadadustat, subject to approval by the U.S. Food and Drug Administration (FDA).
- Business Wire•last month
Akebia Therapeutics Shareholders Approve Merger with Keryx
Akebia Therapeutics, Inc. (AKBA) today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (KERX) at a special meeting of Akebia shareholders held earlier today. “We appreciate the strong support we have received from Akebia shareholders for our transformational merger with Keryx,” said John P. Butler, President and Chief Executive Officer of Akebia. “The merger will establish a leading, fully integrated kidney disease therapeutics company with the resources, leadership and infrastructure to maximize the value of a highly complementary nephrology portfolio.
- Business Wire•last month
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 49,650 shares of Akebia’s common stock on November 30, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $8.08 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Business Wire•2 months ago
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
Akebia Therapeutics, Inc. (AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia shareholders vote “FOR” the shareholder proposals relating to the Company’s proposed merger with Keryx Biopharmaceuticals (KERX).
- GlobeNewswire•2 months ago
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommends Keryx stockholders vote “FOR” the merger and the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (AKBA) at the Special Meeting of Keryx stockholders to be held on December 11, 2018.
- Business Wire•2 months ago
Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
Akebia Therapeutics, Inc. (AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Institutional Shareholder Services (“ISS”), recommends that Akebia shareholders vote “FOR” the shareholder proposals relating to the Company’s proposed merger with Keryx Biopharmaceuticals (KERX). “…the strategic rationale appears strong, as the combined company should require less future funding and both companies are focused on developing drugs for patients with kidney disease, which should lead to substantial cost savings.
- Simply Wall St.•2 months ago
What Kind Of Shareholders Own Akebia Therapeutics Inc (NASDAQ:AKBA)?
A look at the shareholders of Akebia Therapeutics Inc (NASDAQ:AKBA) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
- Business Wire•2 months ago
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-indu
- Benzinga•2 months ago
The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
- Business Wire•2 months ago
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
Akebia Therapeutics, Inc. (AKBA), and Keryx Biopharmaceuticals, Inc. (KERX) today announced that Adrian Adams will serve as the Chairperson of the Akebia Board of Directors, effective upon completion of the proposed merger of Akebia and Keryx. “I am excited and honored to serve as the Chairperson of the combined company after the merger,” said Mr. Adams. “Following the merger, Akebia will be a fully integrated, leading renal company with the potential to deliver an all oral treatment approach for patients with anemia due to chronic kidney disease.
GuruFocus.com•2 months agoDavid Abrams Buys 3 Stocks in 3rd Quarter
David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, released his third-quarter portfolio last week, listing three new holdings. Warning! GuruFocus has detected 7 Warning Signs with SHPG.
- Business Wire•2 months ago
Akebia Therapeutics Sends Letter to Shareholders
Akebia Therapeutics, Inc. (AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”) that has been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx Biopharmaceuticals. The Akebia Board of Directors unanimously recommends that Akebia shareholders vote “FOR” the proposals relating to the proposed merger with Keryx. The Special Meeting to approve our proposed merger with Keryx is approaching.
- Zacks•2 months ago
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Akebia Therapeutics: 3Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. “In the third quarter, we continued to drive our vadadustat Phase 3 development program, while working diligently to close our proposed merger transaction with Keryx Biopharmaceuticals by the end of 2018. The combination is expected to create a fully-integrated kidney disease therapeutics company, with a strengthened financial profile, positioned to deliver substantial long-term value to shareholders,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics.
- Zacks•2 months ago
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
